<SEC-DOCUMENT>0000939767-25-000017.txt : 20250211
<SEC-HEADER>0000939767-25-000017.hdr.sgml : 20250211
<ACCEPTANCE-DATETIME>20250211160820
ACCESSION NUMBER:		0000939767-25-000017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250211
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250211
DATE AS OF CHANGE:		20250211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		25609822

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20250211.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfc7145c-6b3e-4e37-9823-f55aaf069df8,g:ff31b7c3-bb78-44b1-aa92-08bd6dae0e6f,d:4c151b90457e4493a6b2a75c7e31d1fb-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20250211</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">2/11/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20250211.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-11</xbrli:startDate><xbrli:endDate>2025-02-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4c151b90457e4493a6b2a75c7e31d1fb_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 11, 2025</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20250211_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4c151b90457e4493a6b2a75c7e31d1fb_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;11, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended January&#160;3, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel2024q42024exhibit991.htm">Press Release issued February 11, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4c151b90457e4493a6b2a75c7e31d1fb_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel <br/></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel2024q42024exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i06920a714294449b84fdd868e1e262df_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Fourth Quarter and Fiscal Year 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">for the Fiscal Year 2024 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">for the Fiscal Year 2024 - </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">for the Fiscal Year 2024 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif. &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">February&#160;11, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;Due to the continued outsized performance of the cabozantinib franchise, we generated net product revenues of $515 million and $1.81 billion in the fourth quarter and full year 2024, respectively. Our current 2025 guidance, which does not include any impact from a potential U.S. regulatory approval for CABOMETYX&#174; in advanced neuroendocrine tumors, points to solid growth for the cabozantinib franchise. We&#8217;re launch-ready for this important indication ahead of an April 3, 2025 PDUFA target action date for our U.S. regulatory filing.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Morrissey continued&#58; &#8220;We expect zanzalintinib to take center stage in 2025 as our next franchise opportunity that could improve standards of care for patients with cancer. Our anticipated zanzalintinib pivotal data milestones include top-line results from STELLAR-303 in colorectal cancer and STELLAR-304 in non-clear cell renal cell carcinoma, and a decision to advance to the phase 3 portion of STELLAR-305 in head and neck cancer, all in the second half of the year pending event rates for each trial. We are also excited to deliver on our plan to initiate the STELLAR-311 trial of zanzalintinib in neuroendocrine tumors in the first half of 2025 and anticipate Merck to initiate two renal cell carcinoma studies evaluating zanzalintinib plus belzutifan this year. With so much in store for 2025, the entire Exelixis team has a singular focus on achieving our mission to help cancer patients recover stronger and live longer.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter and Fiscal Year 2024 Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter and year ended December&#160;31, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $566.8&#160;million and $2,168.7&#160;million, as compared to $479.7&#160;million and $1,830.2&#160;million for the comparable periods in 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter and year ended December&#160;31, 2024 included net product revenues of $515.2 million and $1,809.4&#160;million, respectively, as compared to $429.3 million and $1,628.9&#160;million for the comparable periods in 2023. The increases in net product revenues, for both periods, were primarily due to an increase in sales volume and an increase in average net selling price.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $51.5&#160;million for the quarter ended December&#160;31, 2024, as compared to $50.3&#160;million for the comparable period in 2023. The increase in collaboration revenues was primarily related to royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, Ipsen Pharma SAS and Takeda Pharmaceutical Company Limited, partially offset by a decrease in development cost reimbursements earned. Collaboration revenues were $359.3&#160;million for the year ended December&#160;31, 2024, as compared to $201.3&#160;million for the comparable period in 2023. The increase was primarily related to the recognition of milestone-related revenues and higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, partially offset by a decrease in development cost reimbursements earned.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended December&#160;31, 2024 were $249.0&#160;million, as compared to $244.7&#160;million for the comparable period in 2023. The increase in research and development expenses for the quarter was primarily related to increases in license and other collaboration costs, personnel expenses and higher manufacturing costs to support Exelixis&#8217; development candidates, partially offset by decreases in clinical trial costs, and consulting and outside services. Research and development expenses for the year ended December&#160;31, 2024 were $910.4&#160;million, as compared to $1,044.1&#160;million for the comparable period in 2023. The decrease in research and development expenses for the year was primarily related to decreases in license and other collaboration costs, personnel expenses, consulting and outside services, and laboratory supplies, partially offset by higher manufacturing costs to support Exelixis&#8217; development candidates and clinical trial costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended December&#160;31, 2024 were $134.3&#160;million, as compared to $131.4 million for the comparable period in 2023. The increase in selling, general and administrative expenses for the quarter was primarily related to increases in personnel expenses and stock-based compensation expenses, partially offset by decreases in corporate giving and legal and advisory fees. Selling, general and administrative expenses for the year ended December&#160;31, 2024 were $492.1 million, as compared to $542.7 million for the comparable period in 2023. The decrease in selling, general and administrative expenses for the year was primarily related to decreases in corporate giving, legal and advisory fees, technology costs, and stock-based compensation expenses, partially offset by an increase in personnel expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter and year ended December&#160;31, 2024 was $44.9 million and $160.4 million, respectively, as compared to $17.5&#160;million and $49.8&#160;million for the comparable periods in 2023, primarily due to an increase in pre-tax income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended December&#160;31, 2024 was $139.9&#160;million, or $0.49 per share, basic and $0.48 per share, diluted, as compared to GAAP net income of $85.5&#160;million, or $0.28 per share, basic and $0.27 per share, diluted, for the comparable period in 2023. GAAP net income for the year ended December&#160;31, 2024 was $521.3&#160;million, or $1.80 per share, basic and $1.76 per share diluted, as compared to GAAP net income of $207.8&#160;million, or $0.65 per share, basic and diluted, for the comparable period in 2023.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended December&#160;31, 2024 was $160.3&#160;million, or $0.56 per share, basic and $0.55 per share, diluted, as compared to non-GAAP net income of $104.2&#160;million, or $0.34 per share, basic and $0.33 per share diluted, for the comparable period in 2023. Non-GAAP net income for the year ended December&#160;31, 2024 was $593.6&#160;million, or $2.05 per share, basic and $2.00 per share, diluted, as compared to non-GAAP net income of $289.4&#160;million or $0.91 per share, basic and $0.90 per share, diluted, for the comparable period in 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation expense, adjusted for the related income tax effect for all periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Financial Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is maintaining the previously provided financial guidance for fiscal year 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX&#174; (cabozantinib) for the treatment of patients with previously treated advanced neuroendocrine tumors (NET). The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' supplemental New Drug Application (sNDA) for this proposed indication, with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:56.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.15 billion - $2.25 billion</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.95 billion - $2.05 billion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $525 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 23%</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:8.93pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2025 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.8% for CABOMETYX effective Jan. 1, 2025.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $40.0 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $60.0 million of non-cash stock-based compensation expense.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cabozantinib Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product revenues generated by the cabozantinib franchise in the U.S. were $515.2&#160;million during the fourth quarter of 2024, with net product revenues of $512.8&#160;million from CABOMETYX and $2.4&#160;million from COMETRIQ&#174; (cabozantinib). For the year ended December&#160;31, 2024, net product revenues generated by the cabozantinib franchise in the U.S. were $1,809.4&#160;million, with net product revenues of $1,798.2&#160;million from CABOMETYX and $11.2&#160;million from COMETRIQ. In 2024, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.5 billion. Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter and year ended December&#160;31, 2024, Exelixis earned $44.4&#160;million and $166.9&#160;million, respectively, in royalty revenues.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal (GI) NET Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2025, results from a subgroup analysis of the CABINET study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the GI tract were featured in a poster session at ASCO GI 2025. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients with advanced GI NET, which was a subgroup of the epNET cohort. Earlier in January, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as category 1 for certain types of NET following specific treatments, and as a category 2A preferred regimen for several other forms of advanced NET, depending on site of origin and grade.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Data Presentations at the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium (ASCO GU). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In February 2025, cabozantinib will be the subject of 16 presentations and poster sessions at this year&#8217;s ASCO GU, which is being held from February 13-15 in San Francisco. Notable presentations will include final follow-up results from the CheckMate -9ER trial (median follow-up of 67.6 months).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Pipeline Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Encouraging Results from Phase 1b&#47;2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with Atezolizumab</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tecentriq</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#174;) in Metastatic Colorectal Cancer (CRC) Presented at ASCO GI 2025.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In January 2025, results from an expansion cohort of the phase 1b&#47;2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab in patients with previously treated metastatic CRC were presented during a poster session at ASCO GI 2025. This cohort of the STELLAR-001 trial included 107 patients randomized 1&#58;1 to receive single-agent zanzalintinib or zanzalintinib in combination with atezolizumab. Patients had unresectable, locally advanced or metastatic </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">RAS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> wild-type CRC that is non-microsatellite instability-high or non-mismatch repair-deficient. Results from the presentation demonstrated that all efficacy parameters, including objective response rate, PFS and overall survival (OS) favored the combination of zanzalintinib plus atezolizumab versus zanzalintinib monotherapy in the overall population, as well as in a subgroup of patients without liver metastases. These data provide insights into the contribution of components for the zanzalintinib plus atezolizumab combination and support zanzalintinib&#8217;s ongoing pivotal development in metastatic CRC. Exelixis anticipates disclosing additional data from zanzalintinib&#8217;s phase 1b&#47;2 studies in the first half of 2025. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 1 Clinical Trial Evaluating XL495 in Patients with Advanced Solid Tumors. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2024, Exelixis announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XL495 in patients with advanced solid tumors. XL495 is a novel, potent, small molecule inhibitor of PKMYT1. The dose-escalation stage of this phase 1 study is designed to determine the maximum tolerated dose of XL495. The expansion cohorts are designed to further assess the tolerability and activity of XL495 both as monotherapy and in combination with select cytotoxic agents in tumor-specific indications. Exelixis plans to present data from the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">XL495 program, as well as XL309 (potentially best-in-class small molecule inhibitor of USP1) and XB010 (5T4-targeting antibody-drug conjugate), at a scientific meeting in 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Development Collaboration with Merck to Evaluate Zanzalintinib in Combination with KEYTRUDA&#174; (pembrolizumab) in Head and Neck Cancer and with WELIREG&#174; (belzutifan) in Renal Cell Carcinoma (RCC). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2024, Exelixis and Merck (known as MSD outside of the U.S. and Canada) announced a clinical development collaboration to evaluate zanzalintinib in combination with KEYTRUDA in head and neck squamous cell carcinoma (HNSCC), and zanzalintinib with WELIREG in RCC. Under the terms of the collaboration, Merck will supply KEYTRUDA, its anti-PD-1 therapy, for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC. In addition, Merck will sponsor a phase 1&#47;2 trial and two phase 3 pivotal trials evaluating zanzalintinib in combination with WELIREG, its oral hypoxia-inducible factor-2 alpha (HIF-2&#945;) inhibitor, in RCC. Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1&#47;2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib. Exelixis maintains all global commercial and marketing rights to zanzalintinib.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Favorable Ruling in Second Cabozantinib Abbreviated New Drug Application (ANDA) Litigation Against MSN Pharmaceuticals, Inc. (MSN). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2024, the U.S. District Court for the District of Delaware (the District Court) ruled in Exelixis&#8217; favor, rejecting MSN&#8217;s challenge to three Orange Book-listed patents related to cabozantinib (U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment)), which expire January 15, 2030. The District Court&#8217;s decision follows an earlier stipulation that MSN&#8217;s proposed generic cabozantinib product (ANDA No. 213878) infringes the &#8217;439, &#8217;440, and &#8217;015 patents. The District Court also ruled that Exelixis&#8217; U.S. Patent No. 11,298,349 (pharmaceutical composition) is not invalid and not infringed by MSN&#8217;s proposed ANDA product. To Exelixis&#8217; knowledge, the FDA has not yet granted tentative approval of MSN&#8217;s proposed ANDA product. On October 23, 2024, the District Court entered final judgment reflecting the opinion. Based on the District Court&#8217;s final judgment should the FDA ultimately approve MSN&#8217;s ANDA, the effective date of any such approval and commercial launch in the U.S. of MSN&#8217;s proposed ANDA product shall not be a date earlier than January 15, 2030, subject to Exelixis&#8217; potential additional regulatory exclusivity. On November 22, 2024, MSN noticed an appeal to the Court of Appeals for the Federal Circuit and Exelixis noticed a cross-appeal on November 26, 2024. In February 2025, Exelixis received notice that MSN submitted to the FDA a Paragraph IV certification regarding another Exelixis Orange Book patent&#58; U.S. Patent No. 12,128,039 (low impurity), which expires in 2032. Exelixis is evaluating next steps and will continue to vigorously defend its cabozantinib intellectual property estate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Repurchase Program.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Under the ongoing 2024-25 $500 million stock repurchase program announced in August 2024, Exelixis has repurchased $205.6 million of the company&#8217;s common stock, at an average price of $33.62 per share as of the end of fiscal year 2024. This is the third stock repurchase program undertaken by Exelixis since March 2023. Stock repurchases under this program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated stock repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis&#8217; common stock and general market conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announcement of Key Priorities and Anticipated Milestones for 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2025, Exelixis announced its key priorities and anticipated milestones for 2025, including&#58; the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following completion of the FDA&#8217;s review of Exelixis&#8217; sNDA, which has a PDUFA action date of April 3, 2025&#59; expansion of zanzalintinib&#8217;s pivotal development program with six ongoing or planned pivotal trials, including two pivotal RCC studies with Merck and additional </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">studies to be announced in 2025, as well as initial clinical data readouts from the phase 1b&#47;2 STELLAR-001 and STELLAR-002 clinical studies in the first half of the year and clinical updates from the pivotal STELLAR-303, -304 and -305 trials in the second half of 2025&#59; accelerating the phase 1 development of XL309 as a potential therapy for tumors that have become refractory to PARP inhibitor (PARPi) therapy, as well as in combination with PARPi agents to deepen and prolong responses&#59; continued progress of phase 1 clinical trials for XB010 and XL495&#59; potentially filing three Investigational New Drug applications for the XB628 PD-L1-NKG2A bispecific antibody, XB064 ILT-2 monoclonal antibody and XB371 TF-topoisomerase I inhibitor antibody-drug conjugate. Exelixis presented the details of its key priorities and anticipated milestones at the 43</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Annual J.P. Morgan Healthcare Conference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended January&#160;3, 2025 and December&#160;29, 2023, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December&#160;31, 2024 and 2023, respectively</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the fourth quarter and fiscal year 2024 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, February&#160;11, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. on Facebook and follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; ability to maximize success in 2025&#59; Exelixis&#8217; 2025 financial guidance, which does not include any impact from a potential U.S. regulatory approval for CABOMETYX in advanced neuroendocrine tumors, pointing to solid growth for the cabozantinib franchise&#59; Exelixis&#8217; launch readiness and the regulatory review process with respect to Exelixis&#8217; sNDA for cabozantinib in previously treated advanced pNET and advanced epNET, including the Prescription Drug User Fee Act target action date assigned by the FDA&#59; Exelixis&#8217; expectation that zanzalintinib will take center stage in 2025 as Exelixis&#8217; next franchise opportunity that could improve standards of care for </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">patients with cancer&#59; anticipated zanzalintinib pivotal data milestones with respect to the STELLAR-303, STELLAR-304, and STELLAR-305 trials and in the phase 1b&#47;2 STELLAR-001 trial&#59; Exelixis&#8217; anticipated timing to initiate the STELLAR-311 trial of zanzalintinib in neuroendocrine tumors in the first half of 2025&#59; Exelixis&#8217; expectations with respect to its clinical development collaboration with Merck&#59; Exelixis&#8217; plans to present cabozantinib data at ASCO GU in February 2025&#59; Exelixis&#8217; plans to present data from the XL495 program, as well as XL309 and XB010, at a scientific meeting in 2025&#59; Exelixis&#8217; plans to vigorously defend its intellectual property estate&#59; Exelixis&#8217; key priorities and anticipated milestones for 2025&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">KEYTRUDA&#174; and WELIREG&#174; are registered trademarks of Merck Sharp &#38; Dohme LLC,  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">a subsidiary of Merck &#38; Co., Inc., Rahway, N.J., USA.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i06920a714294449b84fdd868e1e262df_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:37.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">515,232&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">429,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,809,395&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,628,879&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49,343&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,229&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">349,244&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">178,635&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration services revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,062&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,694&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">566,755&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">479,652&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,168,701&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,830,208&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,965&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,753&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">249,002&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">244,670&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">910,408&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,044,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">134,328&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">131,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">492,128&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">542,705&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">403,549&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">397,864&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,564,084&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,659,323&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">163,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">81,788&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">604,617&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">170,885&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,388&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77,156&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">272&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(137)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(133)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">184,773&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">103,039&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">681,640&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44,912&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">160,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49,756&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">139,861&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85,518&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">521,267&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">207,765&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.49&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284,527&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">308,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290,030&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,546&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">313,023&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">296,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i06920a714294449b84fdd868e1e262df_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">February&#160;11, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:36.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">139,861&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85,518&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">521,267&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">207,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,836&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34,320&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,510&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,265&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,896)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,629)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(21,520)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24,691)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">160,311&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104,195&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">593,583&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,419&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.49&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.05&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.91&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">308,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290,030&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,151&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">313,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">296,132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,464&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20250211.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfc7145c-6b3e-4e37-9823-f55aaf069df8,g:ff31b7c3-bb78-44b1-aa92-08bd6dae0e6f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20250211" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20250211">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20250211_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfc7145c-6b3e-4e37-9823-f55aaf069df8,g:ff31b7c3-bb78-44b1-aa92-08bd6dae0e6f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4ddd8ff5-ea68-42c8-978d-3d5351515115_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3f201663-49fc-4957-9702-b86180338f48_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8fc77c72-7582-40ef-9baa-b222571f651e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dafb2805-8188-4524-a903-7525fb24524b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_50784395-cbe4-4830-a28f-9bcd762d17a9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_cec5fbe9-4d76-4684-b83a-fa6e7575e28d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6070a854-921e-4408-8b93-1c7d23caa09c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e0d9d3df-74e0-4601-a807-fe746a733670_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9988b25a-83df-4fc5-886d-8a9178d89c67_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c9c53329-a22c-47f7-b037-81cd5d935a13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ba0222b4-050c-42d2-8bee-cc5436af7b68_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b42c65cf-bd95-435c-9b3b-0fe5fe664c85_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_29694bca-dd59-466b-b143-a7419cc10cf3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e582c1ba-af0f-4edc-a821-910cecb3edc4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b6f215a6-a827-4e3a-86c5-552c72c16c6b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b469e5e8-e627-4cc1-af7e-4637d58598ed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_89793a61-bcd4-4da3-acfc-8f03055c33ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3ad61398-0e19-4fb8-9bf0-14323fca58aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fa74cc88-d93b-41dc-b3ad-fee076c951e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7f6aadf4-186a-4403-821d-652edbac6c0b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5def92dc-7ea4-47ef-911f-5f25561b2c91_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5ce2066c-4d76-4a04-813c-b13c50fcce40_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a208b947-ae12-497f-9f88-63f5f7d519ff_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20250211_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:bfc7145c-6b3e-4e37-9823-f55aaf069df8,g:ff31b7c3-bb78-44b1-aa92-08bd6dae0e6f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20250211.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b8927fa3-f986-437e-8667-977d2d7b4ffd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_AmendmentFlag_b8927fa3-f986-437e-8667-977d2d7b4ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d9f190d5-b592-4c7d-b9c3-1d584e2fa166" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_DocumentPeriodEndDate_d9f190d5-b592-4c7d-b9c3-1d584e2fa166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_07270d07-dd54-47e7-81a4-b315c50b6b37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityRegistrantName_07270d07-dd54-47e7-81a4-b315c50b6b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f30878ca-5e7b-4d17-99f0-7978e51a69fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityCentralIndexKey_f30878ca-5e7b-4d17-99f0-7978e51a69fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_90b0aa22-208e-419a-a50c-62f9ec889a08" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityEmergingGrowthCompany_90b0aa22-208e-419a-a50c-62f9ec889a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dd03762c-dcbc-438d-b96e-a571d5ae4834" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_Security12bTitle_dd03762c-dcbc-438d-b96e-a571d5ae4834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b08f6707-492a-4d18-bf62-03c3f099bd97" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_TradingSymbol_b08f6707-492a-4d18-bf62-03c3f099bd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_68a54882-0043-44e2-a54b-0002a6e0b053" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_SecurityExchangeName_68a54882-0043-44e2-a54b-0002a6e0b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_64155ce2-3c84-4234-9f90-2f0afd8b7cff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityFileNumber_64155ce2-3c84-4234-9f90-2f0afd8b7cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2576089e-e8f3-4052-963c-49359ab8cb6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2576089e-e8f3-4052-963c-49359ab8cb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a33ceed1-1c72-46de-aeee-36b0fc907046" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityTaxIdentificationNumber_a33ceed1-1c72-46de-aeee-36b0fc907046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_40b0ce5f-0e08-4b99-8c96-e820fb9fc0c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityAddressAddressLine1_40b0ce5f-0e08-4b99-8c96-e820fb9fc0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c94c5491-ed01-48de-a928-cf017fa7b508" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityAddressCityOrTown_c94c5491-ed01-48de-a928-cf017fa7b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8616afbb-4988-4b80-ab5f-77e64b68a807" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityAddressStateOrProvince_8616afbb-4988-4b80-ab5f-77e64b68a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c84ce1e2-347b-4df0-94a5-d669de4d1ba9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_EntityAddressPostalZipCode_c84ce1e2-347b-4df0-94a5-d669de4d1ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e29563d5-209c-405d-8516-18f62ec0862a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_CityAreaCode_e29563d5-209c-405d-8516-18f62ec0862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8e509ab7-9ecf-4010-9fbd-1bb55ca6f116" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_LocalPhoneNumber_8e509ab7-9ecf-4010-9fbd-1bb55ca6f116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_dbdc0260-57d5-4457-b66b-31b93ec32cca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_WrittenCommunications_dbdc0260-57d5-4457-b66b-31b93ec32cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_458ccbe1-05c5-4d85-9c29-648e741bc63a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_SolicitingMaterial_458ccbe1-05c5-4d85-9c29-648e741bc63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e6f675dc-8ac7-425a-927b-004ced5d37b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_PreCommencementTenderOffer_e6f675dc-8ac7-425a-927b-004ced5d37b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5ff80e25-33fc-4f65-a14b-efce644290f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5ff80e25-33fc-4f65-a14b-efce644290f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_103bedc3-b5d0-47c8-a449-92e67c2f6bcc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f449ea4-d354-4a96-a28b-25bce08c585a" xlink:to="loc_dei_DocumentType_103bedc3-b5d0-47c8-a449-92e67c2f6bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20250211_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exel-20250211_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
MD[+\KQ:T>9T5PD1'L&A)94XL'LG+#HKYR\<FTD!"?K$5%/X67$R)B'D0]]@B
M!+T2LOT25(!(*)A'!03H90=S9(KQ++H04$]C7\NH#I%A:B+WOL7[!(:'>1+U
M$1G*1"Y!*!@G*7P1X[,!1,,ERJ"0XFM=!'@!$1'V"4V@@?*>:I,"#Y,S4_E/
MJ !NTZK_ ,6C_8+2L0_SYIX$ 1<LCRG\4>BT^KOPV!]@U/5 (55'-4U1!S Y
M)8EYXM14-#.H5T=X5V68UHZM&^P8AS$-*TQNUJ%R142ZA74QKAUB-Q3$U^HQ
M"*CN$F%:I"][NX\'NV^GOJB.S"<6["W86["W86["W86["W86["W86["W86[#
MB;=NPMV%NPMV%@/I".S"86["W86["W86#?()V["W86["W86["W86["W86["W
M86["W86["P<9!/LW86["P&'?4$[=A;L+%$1'!%?PKF+"240P?1",WT0C,:1D
M4P*],71BQ<(]A'N"<HQ">_1*B0485P^=Q!3%Z@JSBEIP3)-D4M'Q=.C/3RC+
M)46&:-C74"X5%%ZH1.(CLPG%NPMV%BCOH"8 83BVXY>PL!V P#E$=F_4S=0;
M808!WTSC^NL&)B[92FT3&WRD+D..N7C$P[!B'.F<<A.<:<S#[RYR3U+@*<)D
M(\,07D0\>9I!E3W,F%2UWN\R&'<<29A'9A-OI@;9@'?$WZB?CH#%YX-I#SJA
M^N4P;92FWSG-E*7?*;G6#(?('.F;G$G.,#&O8)^DJ;I3A<0'89]ET$V+T9"E
M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
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MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
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M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
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IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45994740145008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 11,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  F!2UH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  )@4M:W52N!^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*';9*";UI6.G#08K;.QF9+4UBQ-C:R1]^R59FS*V!]C1TN]/
MGT U1HU=HN?414KL*=\,H6FSQK@11^:H 3(>*=A<CHEV;.Z[%"R/SW2 :/'#
M'@A45=U!(+;.LH4)6,2%*$SM4&,BRUTZXQTN^/B9FAGF$*BA0"UGD*4$8::)
M\30T-5P!$XPIA?Q=(+<0Y^J?V+D#XIP<LE]2?=^7_6K.C3M(>'MZ?)G7+7R;
MV;9(XZ_L-9\B;<1E\NMJ>[][$$95ZK:H5"'E3DE=K;5<OT^N/_RNPJ%S?N__
ML?%%T-3PZR[,%U!+ P04    "  )@4M:F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  F!2UJ2]2"43@0  'T0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A];^HV%,:_BI5-TR:US0OO'2!12N]%M[>7%7;OU:;]81(#5A,[LYT"WW['
M 1*FA1.D56J)DYR'GX_MY]CM;Z5ZTQO&#-DEL= #9V-,>N^Z.MRPA.H[F3(!
M3U92)=1 4ZU=G2I&HSPHB=W \]IN0KEPAOW\WDP-^S(S,1=LIHC.DH2J_0.+
MY7;@^,[IQBM?;XR]X0[[*5VS.3._IS,%+;=0B7C"A.92$,56 V?DWS\$31N0
MO_&5LZT^NR:V*TLIWVQC&@T<SQ*QF(7&2E#X>&=C%L=6"3C^/HHZQ7?:P//K
MD_I3WGGHS))J-I;Q-QZ9S<#I.B1B*YK%YE5N/[)CAUI6+Y2QSO^2[>'=9M,A
M8::-3([!0)!P<?BDNV,BS@.\"P'!,2#(N0]?E%,^4D.'?26W1-FW0<U>Y%W-
MHP&."SLJ<Z/@*8<X,QS+=Z;(# :@[QK0LW?=\!C[<(@-+L0^L>4=\?T;$GA!
MZ]_A+F 4+$'!$N1Z#93ES]%2&P6C]5<5T4&A6:U@I_"]3FG(!@[,4<W4.W.&
M/_W@M[U?$;Y&P=? U(<CF(T1_!KR%--U%1T>OZ*Q9@A'L^!HHCJ/,LQRC!E3
M7$9D(B("@U\Y@KA2,8)U0]@JT%JHX$08;O;DE:VY'41@?*%))5B-SO?)\_3[
M='Y#IB_C.P2L78"UKP$;0]H4C<E41&Q'/K%]%1JNY,%/K]'KM#L(5J? ZER#
M-4F86G.Q)A\@WFS(6"8I%95PN%[=%.L67%U49\%-S(A<$3_X>?D+F;,P4P!:
M!80+04\2,-^YD>$;^=&[\SP?W$:1KS3.&$EAO<\W5&'(O0*YAR,K&MD4SO?)
M4L95I'B\G7((AN^5CNJA0J=DD<DNW%"Q9A?70(W0RVC^./H-8SIS>?^:>?;$
M851?LF3)5"4/+@(3_[;A!0W,*/S2['W4JT](4Q%*E4I%;9&^@8D"1D:D@B60
MP5*%%2NCZMSAZH\3#+)T?!^W["/D@N[(- +OX"L>YJ18%G%)KWG;"%J=1@]-
M8UD+?-S"CX2C*(*"IV].%^09WB-?1'7N<$F_V_+)1ZJ6, P/=&_7Z]N6[C'<
MLC[X5Q6( G=L6_ ]"[D5E:BXW"B&I151#*VL$/Y5):) *Z;B3,EW+L+J5.*:
MXQ&&5E8)_ZHR4:#-I#90Q?[@Z>7U@2OVFBTOP-C*2N'7.'Q.!B>"RRBX0+OE
M82"E__NX@3_+$'(RVTB!>APNTFUT;CM@=-AVMJP$ 6[@WZ ,&"9L.4\R<70.
M7;FMQ87JRGI0%H( ]_"YC'G(C2V4GV%Z*TXK2V6-2BW/V98?]^F98K<AI(?!
M^LKWM O88\.NX,MJ53U^-7JU9*7U![A/_X=LJG4&9+6 _^\0$)3.'UQY#%CL
MT\IU5Q/?O?U4Q>&>'2;MP?PSM5M336*V AGOK@..K YGW4/#R#0_7RZE@=-J
M?KEA%')D7X#G*RG-J6&/K,5_'(;_ %!+ P04    "  )@4M:GZ ;\+$"  #B
M#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S
M85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2
MNMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[
M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q
MQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>X
MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P
MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q
MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R
M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.
MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV0
M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_
MAOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X
M87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%
MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[
MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS
M/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  )
M@4M:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    (  F!2UH9117U-P$  "<"   /    >&PO=V]R:V)O;VLN>&ULC5'1
M;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<
M7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IE
ML]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<
M9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1RE
MW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B
M]1!DZ)'!=09#K+&))@G60VY6= 9.MO8(72A]95,. 46=W=3%<]0!;\K!XVBL
MA H#E&^J%977DHHM)]W1ZTSO'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ "8%+6@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  )@4M:
MW52N!^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  )@4M:F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  F!2UJ2]2"43@0
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M2P$"% ,4    "  )@4M:)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  )@4M:99!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20250211.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20250211.htm">exel-20250211.htm</File>
    <File>exel-20250211.xsd</File>
    <File>exel-20250211_lab.xml</File>
    <File>exel-20250211_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20250211_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20250211.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20250211",
   "dts": {
    "inline": {
     "local": [
      "exel-20250211.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20250211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20250211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20250211_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250211.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250211.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000939767-25-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-25-000017-xbrl.zip
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M4+* +*^B7NT%IP-9OQ:3_S]'_:<[S?\'4$L#!!0    (  F!2UJ4;\$H8P(
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M49*3U9:35I204Y#3U)&4U-(X(J<MI:6@(*^I?4130T9"?E? KXP@1LP%Y%5
M24LCI*11HG**2)2H#!+I+*H@+840591SE99#R4DH.+M([?+K>^'P""_"$=@V
M/QKD1\JZ2+K(2R!$Y9$N<J(RKD@Y445%9P51180$4LX%(2TMH2@+IIB?7:!D
MCD=@\;[>)EB,*]H#=(PUROEW@ITN-/=UWNE%?3.,,]J+EP?TA1+(YN*+1&%W
M.]<$3!,>:&<L GN:1U).C& L(;IVA5BAL#C0I:#[P<@1 WW](Y24B.= 8 ^!
M*DC_BM?7U/RA&\Y,5X-'7UM33E)13DY42DR2D%O Z,.C\1ZHG31SQ ._ WF@
M">&LY('P<@,=)+IS',6K^N=OI Z+;_. S.(_Y8C_(GVGUU!8M!_*10>+\>0A
M)@PE])_Z05%* 2&I( 5Z'X40E5&4D00A&6=1>3E99V<YE**D@BMH_3:_RQ_B
MX#_AQ_SW@;@M /M/0UW\A]EZ:!S8?Z=W7&N.\OGI9&+F4T(@\<2>Q2% [_#N
M(/_D&@4I21025$K4!:D@*2HC[XH254"BY$6=961<I!'2,@H*A!#?YO<_B?+Z
M?:S**\G**<DJ[([5;3(<QA7OC\"BCKB!YO][>6:;$7D2# X4..&*$TW][PSZ
M]\;</S/H+\GG7QCTSU_T_"?FB/_L*O&_]J+X7Z;D710XSQ/)=]<8JCQ_E[_+
MW^7O\G?YN_Q=_O\K/T\IP&6B"J\_KYKJUF=J&W!=[FAB9JRC;ZA-/%*AUC-$
M>V&@] #@Z87'$A;J-L=M><C: "A  < !20! (''>1N8Z%L0OT[4U>0BK>>"W
M\KUG^^OH3E$]$QX>X#\K#$AO+!X ("8@+.T"KFQ ^#P(>_CCO0EXPG>]S,[N
M!!A*^):7&0LJ",*L!-AM&SY$I-F&U0FPBZ>7"P@3=/9V\70AP(T@?,G/E_"Z
M ,P0A"/\T"A_$.X"83X/7T\T"!/>2F'V1"%P $#\'ID/CT*>)/S>AO#-,];"
M3!.$#P, .;7;+[#S+S >%4!\HT@3XWV:^$TVCQ!2F$=245&!1P_E[X'"XT5-
MP$Y!8%UX-#&>W@BOTP"P;3.Q,/[#3ND71_W+QG^S$/IV&YHW)?89A.7E3]R?
MZ# 9 *"P"/KFRD^<<Q( E%\  -9W/W%\:0! !_9;6?LO]K 0XN67,R<T"BE&
M<.B/\C\2_!OEE^>)$<3]< ^/UO;6D8?@-R2X3_7%\N# ,8'B$?UK$/_7C'_6
MXQ"X/4.!VS.0PPJ,,K27&]C=.YLU'K37/^O$_Y+M+V4[KL'"E+D),#N* ?3M
MS #LVTN A(D*@-FG@"V0'_UF2&$%$$:>-??H=MP3RQ]>*X+&$2XX-/%E&D#3
MS(('Z8OUVVXCOC]#"E "=  SL _@ @X 0H H( 7( \J .J -' 6, 0O@..
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M+H2R#7'DTF7V?5/-O+51T+4[I_4+9R5W?'2JC!+L/61!3!:ILJ5=;KF_IV:
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M)(:,3=5>+IFL'%6."$D\2O/FO-Q,>E/:;*:YY^V&VJL!,UH['C^_>FZJ<,Z
M2?)JA)3D)'+2R2E%I\[XC#\I76YPFK)$:)6S"8+F,:M/[F'TQ7TT35<#NC@:
M=UE; IP%R=B8O_-R=H7FS0.3]<H3K-4!/$,F#=DF;4X=XFP1/V@OJ-LN)<9<
M^Q*/(M=M.S8\PA?@YGJ3):J +#<$D"ABE6F4F]G?),!YJ]K?Z]M =;G?U%,$
MIU3$*B_[R9LQALKR?E,#_<2F\PVW=V*S7?+^GH/D39(7]VD<WV-=;R)DP7?H
M8<;'S"8@/")IH?[I0!_UOI?<.>&TDFIG@4$]33_Z?O7'SJ&RD5<".L59;\7,
MWQML1/H<T0HL9"(#,T>K*E:WT4%7R=!5GS3H@STZU8;,%3;,#25T+!A4['Y"
MPQ*8- =)-;9=D] O,)^NJ+,C24E69><81>(3/5P7N*,TX'JLHT7BG<PGA#31
MW/7TP4(^D>L4!F!8]L6#H=7VJP1S<F8!U%7+V'I*@7TZMB0YBFZ/N'&77O"*
M!\7K7)T'>_O0_K(S,)YE^B$F^+<NN]QR4Z^, >VJ:%^6"5&P.B*$8NCGH7T)
MJS6'OXUN$J#I_RM%N6F+X;GFWW%%$7W$D;:"&=BO">%,UKFQ!33MB[\^H-O0
M7%]SYE*CK8G#<J9 Y%RXYQ6]?G(4=%B>"U#HX0AG'QYT91@4HGVKNXB@>7CS
M,A(7*6O<1@KFGFO[5SB4K2V4;ELQVA?/[DUFFJ.K47A^M@B?6RY^:3F9[+E)
M>PF8CO>]5 9-L?$A9@#$H**N4 28;8HK&Y-S1J&$;&/*4G63PA/RN='PL'*%
M?R 4V"^W/\K"]6A@=5GD'"&\OK+V@^%EH>MQ <RF^*,>V31S>R^;<CZ\;J$;
M;- DR!%E.O5Q?\;G#]JU+EVC+9+DX\?,]S_*YC,3.0(F](:7]K7*U],.,5@Q
M*5[T:8%W,05(2'CVL1?).WG5#YRIAA&RV$[UJ1_#(.//FJ>$\DZCQ+=+K'(_
M&G[G^OA4>5AH\B^2MJM,F"O4[""66K#5Q*JN;>-.M7)G2\<XX_[%O:A+VMY1
M.:93S6/\KJL4QVO/6J&-2(\+B' 162G*7T/>AD_"X8/B3@AE\DM;0&5O=\M-
MN/_%  1GLMZ-)NK4L?XMH%KP0EU8#)K+9NGN&N.MA,V]))"2HQV?$KBK_:Q1
MWWD/E!B):.2QQ5Y;,>.756P)5BL6_H9YG[X_/47K<,)KSKL-08R!"P\NE=WS
MU7LA9;.,*W3V97!?]\H\CJQ88Z:0HB&<%X8UU1'7)+"=-<G#]4*61Z?O['FJ
MI5MT4A]U[!#7BU;:J)769H$.=8W0XCW,FRSVAI&73M,O]?&2U# ^W&"T"-<3
M2M0E)1E#D>%<HF8/5=&;&",=6W-IKR).\2[5/ELCB;AXFG&185^+EM@1(59!
MX6"&H1*(5@-_2]J5S^XG2 (@# S?*8S2SLREG+H.I;LN;;YBG MX==[; I[=
MW3C;44PW/Y)" ME[*$YXW73LT6KU3!^W4]>B^GY+75DC4S()1?[(TY^[+&2D
M<ZUU ZQ1B3VQ!>R3K!<E:40,O7K2L=I:51=\)1]P.LLS-_9.2)+G3C$B;#/%
M@ZKCR*HQ.;6YL2\%629%^^R*RA%>3P<N5%/Y_:@V1);OHF#CY)-/?Q#0S%'T
M_X&>6"7;1[(F#\+UB$&38P0$LY8NB?7, ^>G^EH2(?0Q@UH')#-=S*$UDGCG
M9T]5S@>=Q<9H!"T<C21EM::[T\C\;(*R),K6V_"ZB]F;6?Q8N[%0*[]VQ,F^
M7A.Q/<P.N5J?#Y10/",\56@Z30! *)0-W2PJX@RO5]3RPW2]ZF)'P"&#AD.K
M7^$"8F^/>C*Q!V>*:<96!C0V%#ESC-_&,MU&OVR8%L,:FWT4?NIRH('>0>OP
MZ>0C-U1>)EJ4?IB68O7GT$_4=67"9,/?AOLW#N:FQH8_&SV'IE-*7QV6\(S/
M'E1\%9\U*%S90WWQ.<?XK=OZ;1*2A4ZIF7E5YA<:R1"IJ-=&T6^N9*D%*\0N
MBXDP'*18FZ\[G6;8Q+FH[N<<NQRV$$KF#;TXYH6_>,?LID<&>U'$6W7_%J1G
M/,P/Z!>N[!;&IO+@LKU\!!7Y*"Y^FG5FIQ6A.'8#<8#GPY/:=J%6,MM+?I.Q
ME^K92S4<E\9J&%$*(]M9DY!^ZNL;M@"G_@6ZU>(PTPXNGP,>_7*O2@B7LC/1
MM2:<B60,G(FZP5DT)>RW]7:;2CQOK\#N2.,B%5L/O.3><_:%Z?#T?-7+2S$;
MML*BDD\]Y)A.33_E(='2U4K2\G]N0LAR?'#&2TX ;_V)AQ3LFZ]Z0XZ,,@8P
MW10V*A/@G(NO?-7&UPNN'PS??SZ&33OT6#_FXB5_QJ],S#D4!<#SV4K"\*Q)
M0/7J7:D HSQYZ=G=!7#R>G[LL,U\Y&&&Z#*S?3$>66*K\%%&]UU/Y#UN>/U6
MX!%P_*PB241#PM5AXPM536$GEH-9DJ3H]E%Z/G8"6>DC)O>778*O"OS">$=%
M^FZK^X7C1*-F:IZJQZ\5Q2[7!.IJ)5H=*V3/-N*1. ?IHX9]UKU]U/-6A;RW
MU\>!)]7G_.%3-.]9Z6JOG@L!:/I@GDRX2%U7$,7^*\6^N"N*G?(*UV_/>33,
M7'I_]4KL78Y#62H&T=>R3*U# 5+J4T>7ENTGF(3/(=JK(<_")V%U%[A\J=JN
M1M=B(][IC)I(<V]KJ<0\A5AZ'GS=_IYVT=FS.)(AUN51$XD)TVGD9U^*>,(,
M;TC-4\^C2GVZ2UP)V:8QG^GE"Y.<(U-R'67$I8LP"DT@RU;W"+#Q3_CE29-[
M/86R79#;)#_=)8QO\QB66P6?="9QIX=?YY [?*6YYI82=8MU>+Y\:E;YX>%#
M;>?Q 0,:)RD@YS/84)P-]70*\=7E.F,#['?Q7I??A*>QN<J]XU$>NW7[*/LO
MZ#.[4=-^B'>?@T*6L.:^ME,D%^$2B>A'3Q(PZJ27&""03H'$>/:[%+J*9(LS
ML#:^&0UPF;O*HRQ!^UOW?K'@CE ?DBA4U+D0>SF$;>,V.*&UMKK8@+V&FO8-
MRS9"T/3IQRL2)>B $58MV1J?W:_^_K,1[@LM'@RW49DKYV;U/G$VDX^-2H@)
MD/:V,MB\P-$]/4#&%PQ+7/:U:,XKMM6:(:.C//S9&(K$@ .8::]'IAP.G.O;
M=WHQ2R@19:&N%U[?!#T_*A/5L/[H.V)IS.,&W&%IV9.7T/NL9"&P6/51T#]7
M_/YA:ATX)WFYS"QBA40>7$7$]X_(*URQ^\?)M"7X3/OO.+EE0@JQQ9^;ONJL
M_!'@[5Q_NVGZ,B%S48E?5:7CO"J/J%)K'47,&P%SVN7PR7H_"*1%L$5](QB8
MO[^/6AE%7'0X@<L7PG()=]]!4C5/H9XP\#0U'U\*C+GV[2 3Q83[,K* TE=B
M+5,]XJT B=FA(VI8?SH9BBM#J3Z$G%W^TJ3O,"B/]=(D8:KWO/UL4%C7(WO4
MYK%SB)G/F<K&VU^R+YV(.]\N6:UU@3#US:N3J+LLSEB?>6&&^K:@?X40HC99
M@T_HE+)HFL&,FR46&1U_MTP3=P]2:SX1[L$*9IM]C)TIN<^./*DZY]T2Y<6$
M2$C@SM=&&XCDZ%[VWNA?"JC%?EL1X-/,U!D5\M@'.E$@7?]CX]TZPI[@+UL$
ML IAA7D80G<Q]4:2!W8(BOT;GS%P_8D%SP*E CSCGU3_ QZLVE"5:3)K!1*(
M4-G/':8^I:@<R##JE.S)\.5?>2#+^OJ&I.)XV(*6WQ;PA@%<EVCIHIL0.L?/
M-V\__\0C4.$#%*1E'#7:X3$ 9'/T)D-L(9NN"UZ=YEW(+:C,%C#6'U;-Q[S_
MV!GTJON21A#C=?I04:X#U4:=B@R(#X^E.]<8  :T-C4C#TL"!]_3>\)U9I>^
M\QN;A*Q*'11^+YV7@0PLW3.IWWJ]5HE2D=$I)[+D,R8DLE.+>ZXFE\EQN:$O
MK5WR05JCENZF[!9 7,] =M8SI5(/6O!5C->,HV_P.GZGY 6H+%V3#=J=\N_P
MFH20<D.SZ++,3K&)RB287A\YU6_6T<EC:AYRUB(Y2<R<1.G,<<&JJ/78@6H(
M0)_@FG3-,/;N7AJ(:NUK1X>C"0SW+A^UR.N4+3*_FL!O[!35<D4HTA<:9)D[
MKZ.+X:H(TKAW?,+B1M+04R5_AZ_L+;$E.NA/]PSG0*\8.]VTJ9T]F#12*KN4
MYRLBVVJ%"/7IRTK#?^R:T_E.%="HD#%2_E#EM,W<>TY7"@KQ17?O'$VEMLTG
M#[R.!TETM.%L+1[.ZOB]L)H(]!5+V-/=U=N-^)1QUQGM<9'JF$NA4_M[Q4@?
MFSP/3[%D*3Z^@X:4CQZF'NG45]Y7YJY]#;6R&FB;VREM6Z!(>J&0E%.")RMN
M,]HX?*8D)IV#3Y%KK[H6P-6.U4R\B.&L]<]1,YZ[(WGCE&.NKU'B 8<3PRTU
M:K>BXS'R>X4^>(F9/GYO?_=T1:7.O _V\LCG8?97SUKD?VF^*S8U//"DA<'G
M(..M$\DH[_/7(_W]^692=C@%/GB^%#A\]T.&R4&&HJO>Q3-53(]&Q<Q?6/G6
M'%V2>A7ZRP-$^^T;&OH?5UJ9\G$("$?2FFG>V\PPQV;BM0??/](<_/?4V6U.
M,X=V]6I+V=.L[-<[>*_\#G:BD-!DQIY>(7RV )V;6\^G;D5GJG?U\N7'!C=C
MPT!1;!UB;&7&B],4BTINYC<<K-^]_C2=>+#I@U,^NU+%J>=?YK3[\Q1"8Q[>
MD,A&R!Q]+GU-5+UTO,T^.#,E(V;C3<MZAR=5'B[_G;4.*LJ.(L;>7H9$U"/?
M5%8'@0YT-$^^R;\/(6>84'QOCY7>W8X"[46J?"9FQ-3$\+$P4/4>3LM3HN8W
MY[O[6S*ZDA96)IB.NTJ_[ Z\W^860CW"-T@7[EQ_A/Z%.7/+V3FK:KN8>"/>
MU6OW&Y(3WF?MNP]_874OLT G\R2SW87'.?3?35T1M.6:4UR=]B:4LR+6*]Q'
MUR:JSL_;^%JHK3,*SL2(.[^+2'RY[Y#7<&B,1=OL)T[&F0=ZW0_<7SC[=4X7
M^BPRW9MMN>Y76K1Y&!GHZZ,3;WJ-/C;R L7:4,Z$H,V!E^F78T*-AO#QS1_S
M]XF^RSM\5>!VW*?TSP;4R7?@BEXZ#S=T69^LEN9TID6$O_"UC#Q:;#D9(KT%
M1 _?&4TRNVT@NSD_07HB%!PC)VC3/\0X+%IGDV4NIJ3TY(517;YPJ8*J;G'?
MN7/'RI/L.C??6V?>XK!(=%F]=SMVZNUTSM%RM=-[;$M1BD8Z(<EI3N]SCB D
M#,9*S#@;3&ZTD*I^QN[Y="AC^)5YUGIO+W9S[ M R?H.5='8>[R)BXN+D9N]
M,6!VN'6BX8EN7F-GDL4UF3-Q>4DQ%!6O4VN5_!_B4D9]BN->/'8E87YQA]$W
MGOF+XEUP12=:T35OS)ARN;G')\&IQ2R^P)@OM^6"0H[@$[YZ)-?"%(_Z2(#"
MJML6L/=Y[>,X$5Y[U!/#O1"%B:-,Y[N-1T2.5^#LF6]W5/>>3,GBRA38+Z1M
M8%3#9J1WZ&FB>:74C1.&FEEVY1WWZP)F S9:$Y;ZY/[X?R/K='*@Q2,[O1"=
M]FOEIB^\*IY+W[\IU9E7R+QG.,_2;R#_(6?0E8<GLIYKO,Y3F1^[E+/<P68L
MW5,YD:+'^$K\^D,'NB]EXEQ56*XU^(<__3^//%6B=.'N\8?Q,<77NSJ'EXD^
M*5Q1)G3VE\JCSN@V2^$H[!!OVU&+37<-.Z,DAI*>JG)2@^&QBHI2\C(&Z(6'
MYC[QPX>BZD3\UWP6VC?%KW?I/*PYK*/UZ)EV-[.=?N6>48S'O9'WU;;E!]?$
M620[%\;NQ[?<>MF-]<]F_F";V:'IL*&<G+4X\:6 *=#J$TS@B$@G)=<=U>/I
M!:9PMT++UJ,/-X::.\\Z'CD1O@K5Q*3QR?WQ9FQ@J.>3/.-9,.!^@]HZMOTR
MTWWI/32I7R([['.O9>\Y>]^ V58S5WKAE87;83,S2^ON@I3!#B'FR(29,/[B
MA6\ZNG:Y6X"ZGN<"2<3@GVXO+EW*?3"WFAQ<Q\:TU'QL<0L0)(9-.9GAV=0V
M15'7G"C;;/1FH':.V<M!.5%C:19FLSO)F<9:PGKV/YT3W?O@O5(>[K:E=FY%
MOV?=O??,WXZ->YP[2C^;]"5/U?=LGFI*?#**WZHL^85NAHXJ>4ZVA51^]_*:
M3SF%\R#J/K<BCGXDN/C2^=.I[U4,TFG$CS//F@K(G#__B*3F8.M2'+=AW<UE
MJLFRZYHJ$ BUQ^H7(ZV19C#9^Q45W13/LB\--2OL'!%4Y+SV7/3V'-LQ]R?K
M"<V=;E.NY7DYK;/I:L'X:<<Y?W;6]5NM9GP6J]%"!P6$>(4_#\\ONW6=RE3(
MN^:JC7+YPM=2;F%Q*KXU//:)!KIYT_< RG+%KJX_+CML-MC]U)/70I/213BZ
MN)SD0]2DT+8YRP1N+>:L_<%[_A=I;QD55[-N"S?!$AR"![?@[A8([N[N[J[!
MW=U=FL;=);B[0Q-<&@L.@9"/=Y^]]]GCG+OO^>Z]/];ZT;6ZJM:L9\YG/M4U
M1IL]C\27&4R\0#^@D.7HE;:)SE8,H .8-7,G0D0J=]J-9T!/]$GK<,6,%EW$
M8[9^G/Z'-M[_#>X5-5EQTF%I#F4B%;RI@2,E1L>W$.Q7-ZA5O6KI<+N+.<K4
M.+#_ [ 7S/P#&+IJ\]282Z%<#>@<'JZ1-BB[?._,_SGJ+]+=3CQ]"P0J(S6J
M[$.^2Y5ITP@:GYRNH IQCMFK8NGWSD102UYW,/K\6WRF\#X@$W]0L]I78\MI
MT)Z2?P2IX]!H(\,I JB-X&%Q2_%D2S1Y7:C,_Q,9<W8/%:2N)T%*LL\?,<L8
MJ-LA,Q*$DCTESKY6IIUIA1^?^3S/K_@%WD"*!>IVM3N@_5@3XW,X*\IMO5>2
MWWBF+K?[G:+2\CI.L_'-#/.\MR'*?1[K]^C"RU6Q\R(L6<^HS7O(_'6/%9%4
MIK4H6.P$IE[45 #Q;?[#2Z?S6+URW_ZGWF:)BIN>A"68_NN;SNC19%K+9M8'
M.'W554E3+]$:8O5+M0$;>\BCZ_-[/AUR5LB+R1GPUHZ#7S?_IO?[/?AJZ IT
M^A9QN8+TM8H@I+AK^5Z=X#1D<N^XA5+U1-HI]HK9'HPW5B^V$H_*T8%;-%*A
MJ,/)^TW)6V?RU@E;>0NOXV*W7V6L9;Z-L_XWPG4CYI<9R$WB44^91I4J:*PL
M':96F8UYR=L9I)8.KHGK35=>MWYK)9;] ]A]HEO"$ZU)@3@GFT=YL1T/=/E]
MP)%R -4M[,UU!I=QC/%]5S?H\DYK2<9M=,I2T.]PA'15J[1'U>XWNOVR8=30
MHWN#;['<\DH%66P"8G7]8JGP@Y!OY25W>/@+U2T=DF@MLIS41DTHB$Y&:@E:
M^%_B[GJETS61[A>A60$6:RCPLB>)MZ.KH];JP0=9$[IO^6U,"T\)T;IG%XUD
MTMO:FD,4$0  3B2A]H-I.JMW3&RQYY>D=7,621W$5C/)T*Z>LGRFX9#?5PO=
MW\8V;4VN';Z>0)A&RF0]$:3LYSYV%1/E$R43Q["KJB*I40 34FEE_Q6!8L."
MQ4+:]/+?E#ERBO1EVR5LP'[Q8G%+H1%J2HD-!ELG/1J/@+\(T:QC_K4MP^%4
M7O)_=1G>+B0^E+I;B-)HAZ5NZ49G$5-W>3X];XY6RF#,+[5J#%H_DUK^E6LX
MVX7F+E"L7YOVP_[=57;/]'7__6Y*":.!BD+ZWE?_QY.MWOT+3I8GKKSJF9^W
M6Y+>3R\BFY8,A%[*V+F=[B?@I046C/TB+.K%93?2T9^9J?[JE_=[)_DO!N)&
M*:56+1CV]3)N6?AVMTL:K@NQ^9NZ*>@)5U)SF;;XA=TI=.$!_^1[-9:[=I$R
MTAV_[!*M_1 >H;:QIO_!+;LXNW6-;(JX7X)%NW7I.,\E_+4.L5Q^>];6?P5>
M8'#1H:8\QBJ46QWTD;\K()FNJ,D7!K\$2S&![*1J+R+@O?:=/%X@(NM_D@$R
MG;+[%3AV5[XPC%8W]Q/A RWN N7>^!)7WUOH>?XR>^GM8V2DD)%\^*2?9G/[
M%#DM8=H@8\G!*]*S8;590$(:6ZP;(X::O=GC@G;$\<8)DY/&!S:=_YJH#]OP
MX]A?)6B$2OOUTM.HAL:MY!,K<NICO<I@@=>>[^.DK$W54G#V3ZII/=(:0"_5
M/\Y'%KX\]O0"SWEE)#.N%"ZOA'[8>?\S?VRV*P$KV^F]UWNZM"RF]41Y.S<<
M?$2ISD0!7P<O=(<X_WW:&+_::Y4_Q1(2D,BK<SVY>6@BB^<I WK96V?\IF,U
M;?'.PT@92_U7HC#)OE=ND%V#?!)1W#7[ U#J$"!ZE0 JRTF+SD"^**HLF<=8
M9>$=>J=OTS%M\=O" 54Z'* /W;=T)L^[6C,WO!S86JZW+.P.NJ8W)KQR6]-N
M^!P8WIHU'[[83X\A8J$2(B8]7!A>(TB]ES =7@=BY'[+5YJ;/[C-^=R.KUW!
MFFI9HH*%EG_E?G63WA+L+'\:4OHW.U#7$4BATO[\OQ_D'W,P%6N*3"4G_BN6
M)=0^)M+^W#SH"GCZ[\_]HYN2DVM9H%2;_M]C/NT8Q%):H6,(,$*CL:N)\0FN
M6@@!I?+)J/ W57Z6Y8ZP7\0 PHJGL-+^<]G81"?#J62:?_5.M4*Q[U#)+_CQ
MZI?V%(>[2B'TS'5DG.*VC8H^6M_Y7=,GP]755;/0FQ@KLQPA!OS$2K\D H7_
M 02)OJ+'3JPL@N!)*BLK)VE71UDIIE3*\;]('60QD9FV09"B#2@HF\0RS6SP
MB#PR*YHVQ*Q?FG5*"-*#GQBJ;0WB<?]2996%^+,RG']813650#&Y? ON7X&<
M.PZ8MI]320" &5?,07,* !K:<*;"7-.ZDT)\L%K@T+_FY[MWU3:5;'$J':X_
MS2 5J@<8?>#<L?(TP;,:*<ED_DL^^2,  $F?G[Q(2P GHN0V^R_6>-?WF0A+
MU5T:42+1(OVF7_@@6*OFE=4TD]'N]!'S==YN; @IZ49_J8FHI##AP%/6;KJK
M:I;F#M:-R$)L^&UQFV4-WW#&)D/X<77'_N1?7BY*-\).A_B7K _N;/6VQZ0;
M*0E/4F%&I5.KT60R, B@\PD=T(SI5E2<=)TD+=%:_,/-S;K_I*2W:>X=P[K0
MKDS1+YC[$*X^<>[-6%S]B/]&)?75XTT_ZTK<+_Z[6$/KNJYB;CE.;U8E<D.X
MD/#8 +:12$I]S#2=GGW'Y],;G99*,.NMFU39%Q]%4\[\Y 0-RM)20#W5(C3)
M65^DZ_X2(!AW5'D(;T%2=@R8K6PL:?X:DC+=,N];TBP@ZXP9%ZU@EDO;J$!*
MJYM5E%,05QP#X^NLZL>47P 2S0WZFQP1=OC^O@/-OP<Q2#C+-?C6"I(LYRM8
MA6*>6IZRCK?$4+ KA[AU:7Y-*G[4U-3$=8!6.DO:-M>.W:?=UQE5&VU-J$QT
M(-4@V_I:(]85JAOMA=".?8WES/ OS89UE0GHB7[<$(04,^925@ZB-.9.KZ_=
MB^T6;P] _\L7M*-6Z1_NGEOMP7RS$>'A,>&5_GD8,6]Z?/('X(06[_OW[@6"
M-WWZ=;3][-+W^1G)9NEBQ:OU__WH_ZO)4?]R54O5'.<0H?F-F-Z@/P0/O.O_
M^/_O94R9%*1_EG\48A#,4S0:/CC';UF$@/^:._YW1H[G<9&3S8!PHIV!" U<
ML)H8EMEP<'",4DQ14Q9*ADQ6*F/,V!+/^$&9*C7.E@;DV<N@\OS O[89J4PM
M*&-*4Z*#[Q%#4VXTX*]AI6Z?VK#>1T&;L\+BQ,_PJVC!E5+-Y.6P(F26G:*T
M69EJ ,\-4L-()V7QACG18!(9B1!,V]D8NE+/>7</5Y)0RW:;A$_L8$HQ[8E_
MOQ4VH](NE$-B8A)#N$*%]IBFUTW$O^A%*>BU4&FE9Y!1&2=^!@$ Q!?9R<!"
MGNEJNT5+<^X98[6M8F3>1"%.!!K)7>N4[Q\^($,CGHD.TR#JT))"^.](1BO=
ML,U3S-BUR SN*5W4B$]HA$E)Q9SD$^?WUW7HGS'B8D/D@H +77HB.7;7,6FB
M,O>?W;$P293/RV)B=&:,0ULS.04=2-^?Y5_5_L<)J7=P7P!_ !\+IB@Z711=
MXKR09C M/<+3?\YFD,1(O9NW?K?!_1NZW_86_GV0GU()CJ?DH=%C?TZ)8=\6
MDD3E6.8"'2?MUI0CT8)C30!/]"2+B7-!"RXL%J-C3S2C9A 0@!1>8!#)/IB5
M*L$3IV5LB_D%_8GU0HR"B?#,;2D LS(XO;-=)#5<>]5S".ZR"Y!< ^GM#';W
M/W["SF6_5A*5>O:N9V?+*\$BN],0G&N.QPK*9V/V3"X0EYHCO'#:'9BED\LP
M!'WX3"J^166@' ?:%"C_6(20@:Y)-BL6HOB6\=50*>\VP3OZ;2>#:PJAU(_O
MK<];=12/7ZNH&U8];9I>C^M]AJN52F#S OUQ.:8,N^>:OD&5F>EQH&XUQZNZ
M;CB"I]1EC?X <'__ 903 0@\&SGSZ7$Z!)QND3NSV^U>.IQ)UY_;/\ML2PKR
MQ<]VVUD4<5]L/];P\S!_YCJ.8W3:'9GE8XW(%/V"5M%[0G%EU?-33'D9>NO;
MLT2MZ"1'IVKTLL-UM,X-62RGC7-NC-3,-3:48X$HNCD)5"0'E&@"SW+]T%3Y
M*BOT+(\Z.ESQUP+BD&%J9PC1_*\AS^.J3)EQ=V;H<T.<[%!L(18;S;N,=3==
M5GQD0:>@VBU': Q;3*L;APJQ\5;J^^P9J!_FR)EN5 X^'F(B;.GYE7.5QZE/
M<=V?/U5>4_736C?I&B/+F:O/AN4(P\$XJQ<Q8*O\.KJM/5 XS9_O326_*J[6
MN"[0NX/2;]#FJ'Z1B(KF5($31X?1])3-A. A;\W:D^U2Z[A=E>XH9G!7V1G#
MTSJ;5WSE[:O=DT285GO%),@TPZEZ)H]PB0>/2-9L]G/F; #=-)BZ<M^="2F2
M2=5!694-*2N>(?E8L,WUF2N\DTSAS.DSB^2!TBJROWX"DM9^K,J:R;"Y(?!M
MXI\A)N%:$S$V"MY_X/(>6%\IHI@41%I 2KVP#:QOBUUG-D3IL 7B!^!+.(,W
M!E1:).3"1=W57^34$1X_^6?0V:4\>,MM<2"%?5.(1_)=(>;MRBRBWH4_?[20
M !]JEQ4OZT<[Q>N*QW_/,.%4A3IG$NN.S>NE\!#8?*SBC#BF^3WE_JZ+6\5#
M!W<H[CW/R"H;630##)80P! VS^2+IB!_(5Y#Y4-R29?NP73E"2',%N6M':$9
M_\%+8RBV:S&6XWL>8M)&:!Z(V.^1!@%S$(ZS5L9@LA75PL#-1_A(7GBP?,3>
M$:$)*A-Q07_JSX%35$;-D(IZNC7[I&<-VIHYOIB%ABN:9/WN4W&G$;GRJ3I-
M)O-V\5ZU)KM=IVBNS:(#/%2]+MH8?O9U/PTFSU_%DJC,*]\U,HSN8!\\0!P5
MD+K#_!GJ*/:*()20(#9BZX99I#(8W" &&$W+1M0['+-AY+BR)K\5RZ:U&"Q5
MT63'<OI!&>U$1T*3=9N?6):P3KN""Z><3*YJ-5^4]XZ^]XYC5<',>!2!-U"T
MFT2'7[-MV\8/E\NZE3"1D(0;10Y*B&&1+7X/XSQ7NE-UL;_1 T46I?4X[I+[
MROL]=3]M/XPQ<E$L>8&-2%2^]:K_\ZV_N-5Z&EEF&?["DU'XATT/]_4OBT:.
M$*09&2BULAJLOY,"@>JB.5&'J)'(Z:4AO" )S;.B*>M23Y9V!5H:POM!4"FX
M,.(E3E35N<@!X\Q($Y*]"&%_=(ZQ:*MLX#VZCYX6FDTREC/-EAH\)KPW7),$
MF8.I+J+"3'>.F8XH8R/+;1H>(=\.5XJ9T;0(1!D_PK-#.+G0BQ5RO.2'*9[A
M )IP09*ITRY0:9\5L>8H9 X+ E[NDK5N<;@OR5B?./45Q EK5$ESZ:[I&^$C
M3F&XC">JXOOB*YQ^N?(/<_%8&*O99>^ B1K3HF=RI*\77Q@\9'ET87<_(["W
M!R&5!#&3"_'BLB8(]T4C8SM6#,DS&SF@-YGZP?)?I$:PN%B K485&W&3C.4I
MUET%Z>>V26M;P$KI.A=+4(J8GUX*36&F]'!V#W,*PR+,!3^>]6ARN6ZL4242
M!<DV"1)D *<ZY)[%JVYA4BK$[,%J?P L]1*$0=%4BOM%$5#WO02/"-Q1=20Q
MPBVQ),LMA4/(.<8#+Z[^\E8;*9P^RG\ '(VJ@ND&.85'#6C]ME.I$U7@N=.P
MH-$DLC/K^^2$IEFI=*WFK'N;L7O$L,!]5&S]>8NHAUY<RY(G<:0P<G[5_?YB
MT2U*%TT)I2Z"[\#?RO&Y9-;O8MD)0]<47 VV."#A[]5@D@P!3<F&F >3@7E[
MEG<2BM:]'Q/P#3CH/5WD_#+SDS<N)0B)4[-\><IJ)F?&SE90A0;<TMR/=%)Z
MTB&'OW]!^V_A6/X!R"F($F6>?ZK#RVK*]\CBU!51:HOY7J7TX-6US[S,:)2,
M<&MX-)2N<A3LT8O["\8J&0E+F&*?^GG@-E8$5)PE>.KR.?S0(AX66>@/ #AP
M7_V857_]A8O:,RELD5?Y<D_'34+,HMK&)*[AD^=0L8"K5H1Q%10\FNUU_:^S
MSI!&'>%\\'&MY[(S-!&1F+'R\GD )&[!.]15R[E/30D V^>%BX]6W)^)+=LQ
M!NYL$(_<I,J1[1U*CLYAC2-6,CI:V:)R4930A];B0.!_ZGI@^9)60$N V#GV
M2<YOG,DDX2X+V$"IR<#5J#_"!FD<:TI609C=[I\F-QJ=*Y55KBF#^12_/N!9
M*VPNPVQ&$AR(J76J5!^N%EJ\SDH^H7% >R-G(%0Y->"<YFYV+NC@>!%UE]/V
MCH1^\F^HERTB'55OW,>-_YKR5V>#IS*L7\D%;@Z0#R%XRB?#.8D\J NX'I:?
MOF+^YXURR1]QL8\C1+/OZYS1Z,$QU%'6:(4XHU?QNC-<Z.901I(\Q;("X =7
MX&[=&GQ!^0/'(T+][>>?BH_.QAR]DE<N$L2 'QZ!.Q6K\"4#I1?5JUEG6+\P
MZ,,'_5)6WA*4]\[W5M64HQP?:+;Y/G.Q=\" =P#$@,[9;-Y\9$X5Q>;.D26$
M#QBUU5D'.JO/L(?19))!P#VJ:R>JA6.%@X-\#%?QDA,B0<MEQZ*QE*YR$X#@
M"N)4?SZ2^KE.RV?&T;?0+Y_-]&!6@TD.P)Y["#9B5@J*LURV6[:Z^3@2MSM=
M=.>W-_]<4SN;=:$\Y=#T1%+G$0^T$/OQ$*CXFI7_A'KV6],;R^[4BX%G=1@9
M1;+/6:Q0["L+9L ? '+^?QSP^KNE*M\. '8=V5M.8*RA<",@K^LN</1%9S@+
MF1A'C34T$OA!#ZM?,L=X4:!V]>>4@?.@H8C[V?<GE:L8R> O!&4E4Q6;L_9U
MWD@UI4H)@Z$8% V>2ARLKXX#@,6SF?\&\2_81V510'7&C:I%9INV_XWPSUG^
M"7   QB;>DF?8KX'-;QKXB.<>ZS<-(%XN"<XT@MG))=I:\A') ;Q)4@RJ:O<
MY0T:?;G^H*]V?.KGR[:==,9Q?'*"ZEHQ[2SPS6PE/EUS(_$%:JGT8CD!<.8@
MQG-&R%K'I8\/#E21"$ 8C615N(D@%J'\-L<Y6>T4S&$=N!!0E>5K-? '8&Q8
M^P> GQ?>Y6U0CMNT)$A^5MYE9W]<JTOST>H6\4HR(B6T<\34G^(D<F7<Z9>!
MZ:\G7IO?(U[:YRGEKR+/7]0)8 IC*GQH\AC^DH<"NWV#48/#A7RBF1\3>DP9
M6_ !83,/GT"LA.1#5J P:5RY?"S<D!,N8G:GG6-"I1AL2YIA&X-? 03>S@^&
M[F6MU,\5;Y7,G66DB+GV\OF2P0U'%/<97#25]+42#&!B7:YDRU)O\DT*MF%-
MW\)AJEY"#9[=1][T%_Q;>E1'<461?!PE97$YC9OPCM6T;#J9&A-%_WQNQ0GE
M5>R 1-)"#2FHL^DZE ^ZN(;1BD?#20YXUR@&W@?K<%RLU+\ VIQ^(@]KK6<V
M/7T6\QEN3)B96;)<N46XI;TAU);<V.R-I&(VTF06('V'I+YY5F"6\)Z,Y#JK
MSI;_]*WZFOZBXN_Z!W!$7-'+*[(MHL)U]/4YIO\3\)X@&+R%-AU+Y9SBQDRR
M+KC5@Y7?6:^A\SM$'WE[ENIA>W*XD?YJ64,IXER1O4P#[HZT%T$,A+?T.'M=
M]B&.EZ;)<X;=*8]6^)Z2B0,V:_4VF\VLSQ)&2(8EX-V\7%"V(]NARXRJ&YQ(
M:>0H"OP650;9^YR?T)P<"+);5#<Y(^H 4UB120ZO.")M7K0; O[ 3:K<=F.:
M+/WN#0ES;LO,Z_21%/+L@F87\IPNX]^X%>1JG!FYIKFDO0YTNW6K;VI0XB/G
MCJA75@/[^H-^,5N%S3[J0<R"+7UA9P"58V"ZXF])_(M-;#@MU0WM"%9<)8KS
M%;$J2HC55>E[J5P,9O43IF9G'B_2GDNZ'=(U^-_BQ/4.@TNQ=-N97<T@DN*J
MHRR!<A++!2K<1@RIP3?7.+*,FIYE1.L$#?:/MN9?'H>#B @_6*4ZATJ !K(V
M-?;EB$3GX+\*X\4WZXM8DTFKGS^2W6<OTBU7T,.J_?5_E)KPJ!,R+.E4Y%3^
MB;N'L1+$3*@%PZF.(Z>H9$8Q)\S(ZSI8O386T/X1KSO4=B4PDRM%OS=0% ?D
M/+PXL^7&6^M'O:<TYCR\WB&T;@W?V\X 5>EWK*)\-=;DS)<OXM\(<8C?1G>#
MY%OE>YP]KH&0X99RDWX]#1?-JQ3%#4,0OPXO\*Z*K$0HV AN;D0\A2YM0]))
MQ;VY[O?#<56%M-9J'Y07^Z,QG(U0I[%W<4.KL<VLN<B.S)K<U^5+_#L1U K'
M$O[[;ZUR'"Q46N>NR=V6YS9SK.F_*IKI[VOUY-]LT]<J$C%12]_)J[TVX+>6
MLDN_#DWD'%=!F,;=F8@EIA*?S;FM6S1")#Q)DFTQPSF+U3VS812!V&D"XW/T
MWO%/'Y&(/Y]:?SN,XZ?[/>"EE^#+(4#&:VK(R_TFZ#^;QL*3WFHS !U5?!>'
MT&(Q*#CK"__>,06.(.94^I*+C8H^,/I$*6+6ZV.(TB#J(1M<?2ZQ>[9U5KR6
M-STK^77Y4 XIF=;Z>7:"_Y[C9!0 !@"$,GS7QXJ/V";#IP#GFU[4O=?D#$TL
M_(V2_3$I;,9:_\TZNEF.DX1DA+Q;G>#?R<2NQ>V))OOZ%\U?I :SI4:$'R*[
M!M%YMN%L#:F?!Q>:]I//\ . 9L>,0F!9*N?J-I1TNL:Q&.=2?3%]I9]S1;N_
M(.J+945L\! 8WQS!7&*6W'O#C6SE R:BISND6Q6/!.AK7+R.VK3V+;EA:'SZ
M-8N4N+\,P2O/,:;3N#H,F@-<$?6\G.6;Q?W$/13.<DQ#X<HS[2CL@%=G;HDE
MBOD>*@ +:I!=$"GY#Z">^<V5Q2K('GH3@W8DL\8*7\'L&]CI-<OR@LY'!*[2
M!5>E0\F"#1ZAN04TT X%B2PCT;Q(SOI!KWM51@46W;;68J=<3V)5GM7L7C?9
M*1?&"NL[AC@HL!EA2"5H8H.:EIU]%55.P=&>V3D<!T5<:U\Q#G,+>-F8=GW<
M1D[<O,8%?6 'S:37?7]5;@D6N!)[YGE1!WU>A:.W?1?F.QX:U4JV";\K=]@-
M=84:S(KP9/A[ 1(7?7'SMFPHFLQ3<L;QG7*?)(VJ=,5%U05+)49%IA.PDL62
M)"(V%"Z)XM\*!G[*C ! )%4?;,D^S<\## H9/O(J!Y?:(D:\Y-)K%X5H:MO[
MTE<KBTXD=G][Q2O3J.<WNR7CM[ISC'OI F,VULB32[PPS:_+H?@'X #.-B1&
M#Y>,"SBK.#)>0[A-]DQQ3QC1["*( ,YQ9?*/H"\ZJ&1E-9G0>[*1C:71@%^5
M!=[15QC3#P)8J,:I(*G7XG.G/$?$/84)!%_H.O,)ATR_E94_-*\BG)./YHX[
MA;27FPO@I3M]83\:F[,#@VP4[W2U!KW*R5/Q=;_#*0O#[3(0J1/K93^'?%<>
M,GO^>_TP, &<LHRTB3PE>C-1FG-E4\;3PQ394H+B9 'M5Z7?#00K'T*["UPE
M'O!$8#,?Z:YN=+A-[K %O>)"NM<U>"8YC.6%U"VSNPIAT@!$\RY4%*?;=H=>
M:SJUYNT:;!!TJG'.*^YE6QS:S6+2TY:%_67/:F1YWE&[/>R8(6S;,J08LA)]
MP>7H6&UD1L,#\G>XQLB]MI;/G>HM%:>D=<\HAD_67:7^5K7'6$_MK2?!UJ9J
MK/+)'K$B)$[;5LFXM$"*9,-W"W(9D33*3+LC35N%&JDAQ>-I=N*'.4,0%P*G
M\IAXAH;@^!Z27Q73W^9>K/YYLX1I<8AE;*(T0O,:E[7EC'D_,_O.?K>4HQY2
M<$1L.!D%(PRK","%4B2 =P9G]XLT#;Q)=;/]X$IXX9=8YJ^VCX12<P2^>T-]
M'H1OQ36_."&L -2ZT?1WZZ:E8RFUD5 FJSM$G"[K)2+DJ*.V54*E%1Z4B*Y]
M9,1VRLA(JGFY\MD46"Q<S]JF7U/18**VN=;(%=5*G^9Q@;(=B:W/&8U$)(S0
M %B1V?S)2?14*O@M_XC=(T(1?/:_Y6^3^Z;LT,-\M+,)[43ORGRK:I,A0Z*0
M9>WWC6B P6S8C^Z:8J*:NT<Y;HAP7_,9.O.AD'LON'3 A.@C?OHA&]\R:.52
MIJ:JP?!W!, ?&P_F54L<X2\F#Z\Y?@AE1QV@,3%-,9,) 9-QBK[Z2 JA^<\O
MG-_^XZ@<U-^<X>09LD^:]$2S<Z,./::1=IEA1W3N+C;W]T6]"(*!CY72.0O.
M$_4'$VIZ*F+IAJ?K7N5!C >'"1ES0DP1>IM.?7GQ9[A)CM!:O+A,>+LS4KPY
M^*BA%$DTQW1XQJAE[)(T;8%6&*..:EDJ@"]QBL&BE:WJWPVDF![=5.?IZUM+
MCB6_I-<OF2,VNBT0>S5ISP8RF*F\4Z8XQJ\W7ZV,G'_/B*4@L,*F>M>:M3_B
M'!=$Z.QFF'= %M\6X[W+,S8?-&=;KJWCUY#':TUKBDLKAA&J^ 7M]?NW[!^F
M5A!KJ:@9\X!@%2UFW(L""D!E<PY$::,/+^W$)6G)U.42SQI,/B1;.4EE%#P-
MIFQVI5YXOZ=*B/ &2%@&VGO^$;&V YDEM2@@LX6VQT.FXTI('2?+*&J#'LWU
ML&78)T9'-[+8/0IE70]QAL5+#&4A."I6>3[5W. ZW4;8BVI+._4,_**6BGO:
M6N9/4B8! !N* /:TWX[($C8EZL%,Z[B0DK(1C)E)LV3 /+&4> &[[XYK.8N!
M2XP5 R_W]^V6. A,7X!P.E%]-\?QZW=[G.B4W:P?-N5)H!;WU<3!TM57X5)_
MRPZV(GE9=1\? O6X2,V,0J7&CS]XCHQ]=#/*R[.DO:.\L+6M,S)*$D?#O0AQ
M;9!*C%$2EC;QX$P:I'XB]4<"^4$%(XHX&;(9G 0CGB[.6UIZ)G$<#!0Q0FJ*
M+!3)0  [)Q_!&:M8G*^5EM.[/>6,B@JCUZQ3=.CSIV%,SJR("4T[(WN\)'D3
MA4_(HRQ+-187?C57AW/DL=C<>XKUPP4 $ < L IX_:X\!U/&XR(VCD"3X@WR
M#%:5%B!?"O 3U!-+J']DM&R>C"42F#$0]3[>0,GMWTO7&J"O5@N1].XZ<HUL
M?LM$=;%A,W\ 5D0+*U9 0NU456,%(8!+GE$IKRX)^J%LO_I.Q@?"1?N)2_;7
M%&K'^Z'X+_?(":: .RO72A2O>O;U^I?P]&08[MUXS>N=UXSB;)]7\M37U8E4
MDB.938JJB<!7/>G5"J"#^?J@2'D';UB##!LV9>YJFKDY=YJQ6Y+48'*K:+<N
MR2GKO:PG!"*"I.R]!U;YZK3XU6B9^9Q)X1[5J:HTNKIR_(X9/*>*,8Q;+QT
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MKO]M5"F<2/%=M-.P'=O6R9@/@V&;09PO(582QGMZ0?F,46F:R0):'2,%XMR
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M>U%.\/@XE^XD>$=E)4W P!.*LEVBZI3,FE:JY8>['U*(,&F\+.^TN7DH3U<
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M );[7_$T"4/0@?']W'^/&K8SG)=&MTFY;$CUS3Q'?<7B5^K=-$X,MVN)ZIB
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M.>8YHOZ2]L#\M0LF##JXTNK^/OOL\2"1./0'4'N^1<;#13\A(SN6YEF$?^<
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M3\IPZ8IIU!SW+JF#:W)DI]7'1<4_X3CUHOY4JV:/[\ODPNC&^FK!JAD"TU9
M%%G--#&HLY!&9C@3<D:656V"]):__C'2)UM#3\9AR$FUNJGSLKA=Y0[+S'[O
MY1=4&CWG^37@[ 02T;JM<4I]#A+6H1O"X_(5F>&(K;UGGK 18/9]+_#+1:L0
M,;K45E1=_>5/6T@$.B0ZQ['(=@G@+<V5\R2<3K=M6IJT%","AX."\8VYM$[]
MWIOCY0UYG1/YJ9CKZNL[ [T\:S9 S5Q(&N63!0 =WN!(6H JBGQ68R:3[8MN
MSX;W]]$!;QXG8(,M6PJ3'K/:;D:U_8&9P;=#XL74-\@(;P8.'._11?$$F-3S
MY\7=S@_*7/_N@#.M<KK%O*<14]P3 "4^2(:S0LNYLG2:?-R^,OL)7@."@M=.
MOE.X,"]1-2WWX87RKW"P(S18:@L E -)\JQ?P_CVSLB0??!S8J7#]5465=J?
MG4TO(K>55#.2#NG39Q)^+HU[JA771F4;JU $9]& EKAFO$,J0HDC0,9C*A;)
MVB.N+YKX1IQ*"<[O?^AA<+QUZ?[^0)/"SVD^?KSO^2B]'\[0IM/$#E?A@R'1
MDA!^K"&U(T.OP]L#O2$>P8K WSC+X9J2MXBN9&5#=?3<V3SNRF9_0]3"QE!]
M--W2!_W,(AAXTO'M:C4)E13"=C[J[6C<+WO^+'DQ0PQ(VU7K$E_TT(G[,#DM
MV21S,EQD1$_?#5IARSS7R.K-^Q/_@TPP!1O!IM=1YG=47)=]?2^NYC754]9-
MVIMG=58  $ 8X 1P-V9ZSAY+Y_":9\+PMF#0"'7V'!_J\!.RS(Z58A,<"-$1
M-G:;&_DCIY.RYS=.+M*OAK#%&B]L !C5N31>@G9E[.II6@-$57O\O6#V')CT
M?'+WE6&I/ENC!11'K*GO:R=2,->_1L\#\47*14BGX_ X5SNU5'D3E\6.V*NN
MR-N=^[8X7[HW\BX@"S%!JV1-X];)-E\&]C:4>@/?#J2!+FY&3Z)28!QK:.*:
M.J;LT3#Q0.!MTMF N*I7Q#./T'%AV6B3?5)D855^)B^W,[N4+/1)=]+,R2\
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MC[E7N+I-()KC&7XA12S>U&Z2!XE?:2%1E8!EM*NJ1Y,8,#[?-Q1]] "RUNF
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M6FU@X\.0J?$2X#=8K?^IXG?RVV ,N80CA0"_R*\*IE(#G>[-OR.N@,5@F@$
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M83V8N:\!?A;Y ,6MNRY% 3=++*(8(:DG&X6Z\S^B)C_O+.K28$[*3#/-3:]
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M36)DC$(J8900#4--8L@9)M!0*H0)(JX,^^GJC3$$);$D,$EB!L,P05 (CF'
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MX+>OVVQJ22>]$P??90^_A5[EMX5<CWPVAVK47Z=UNLX M%+X"=1)@+P FT1
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MX4^F@3,<1<S4S1;[S0^^. ]<?A\YD2M^3L;YZ4?Y]T\_TB0_]7U[^O-/MO/
M'/OO;QR]W3-UWC&:9J_9;/;ZW>; MKOMKC"$V3;MP7^--_ J/"[?":.I*_[^
M9NQXM9' ^=]VS$ET]NC8T>BMH>M_>U-X+A)?HQIWG:'WEE8+WPY\+X)5!#"J
M_.?<X M>2KZV?-</WGZGTW]G^$UMP,>..WW[/Q?P5C]P_D<+N1?60A$X _E
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MGC"HC,_"O4799WV$P)3R:P7'E%M,(ITF1\H<DQ>RX934AW?EOR14T0.#.;9
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ML#]=OX&=7%_>G\JX 5KP>]^7R>CO@GC(SG.1 B 53MZ_.S]%C.2A\N"(1P1
M@K'_*<J?:_&HQL( )E7&X22\QI'26@\ &1EKG95ZT.2..-7^@"5/Z$4:Z3/0
M%'LOL/Q<Q$ZH\,-I6>4' $^A1L1VY,3V#=\M8R/#=[O>,9L;&;Z?_J[1:S^[
M.;V)[MMG\0LE@(<#1^2&>_8GERQ#$0::;-^"1%3%4U">GJFOT)4R\\VN;;^K
M^;2*.3O/:OSLU(W6"FLH\0DC-&L-X)5YIL(;BCQ<V<H&ZN4X*IBNGQPDD.M^
M(2)8XO]XX?+$Y12"Y6);:5VD&AI)S=9L^=C572)'S$O791EK%95NATJ->F^&
M2O4Y*CT$L79BG.XS4VT3IQ>8(P1ZX=!'RPRLW"Z$7!P2&^U1%$OS;\ >K;\A
M8,NR5.>C6O:![+8NRY<GT%2"?3N"O6=F=1I!KO<ZZ9\')=;-O1;K6^>OM1(U
M*E;;#JLU.P56:YF'R6J-S5E-67/*L7YDZM4E.>N0T=!U%^1[IRQECB?A]"SL
M]^0,KX\W30/5-K/QMT6D78RURZU<;5Y1;S?9ON.A^_AM#3]YKKWT5O(6_+?D
MOX56V\+JN_5>8W;]O>=;?DL*EF4[6"R7C&4W._:\X86KP7O6T4=>J=+J.JD_
M)4#_>E**AYS=28EJK.8LG0^/(]\56%."<>O/V)$@D74=TIPLK"-;[_ZM6*Y:
M10F@X/DG]^K,6&;PWR(%OS0)9%K@%@D B_Y+1'[?U.MZ>L3C#3 )S%@6__$J
ML-/8,7;:SX^=*OEJGQV"5?)5E7Q5)5]5R5=5\M43R5?-*OGJ!9*OMJBV?7,<
M7:&AY3_@%1=?.^34C_)\M 6-.TL[<Z*LN*52?PX6OME%VEJIO[M0.W!Q4Z$D
M2%1>)57MS=9L&5U;%L<JZ<24]K&BP+,G:L6:<X5&,/8ONXRJO*]FV4/XR.W5
MOTLC_##Z;N7"D>6W[8TA55[N]FE(&%H'5,;9,L4EL#",\J<4,"A#0^YJZ/I]
M:LI3NNSE>\X"[#W9V"TI)HEI"4(@0 $SJ1>_SGZA"U \03M#;M*T'.;J4SY=
MS#)/=VN5S,GEJ\ABEE0_9X:V5!&=]EQ1E&(E':R#-U/*\]ABI]_\_$Y$W'$!
M3K>%!E!Q?QCX\82=)TE"0,$WJC<3D.O5]>4]NU&]I>ZBV ;$9GV&"E(4H'B>
M!-7^RK&E#^9EP%8Q$>3DUZM31F.EL>LJ,>I\#/O!/)\[WW)$-*6(WZ3,WB?/
MDJ6QY@:\H%9"(;N;8CEB)QZSD_.[BT_LURLZU4]W(Z>!8?_)/50R5 .E0GX1
M95!(</,<N!$*":A# O%< #,03\!KH)"@M0]4J451RV*"<<N,!PZV9DKD&< $
M7@=.)9DV@!'B) <#FQ-2+S,A.S4!4O)@E!'0Z6+#D?^(=I$\VC$!F(<A((\X
M7T8G>TF',W+D.UDW2IBC-@@$-CT,'AP,^SZY>7]WFJ7\RGAMEUNB[].+!3BD
M4=NP/MAIDO/X*+M1)<!5,"5@P,@C/XCJ[)*#BH/)(BF*9'NKZR17"0LE!V(D
MO!#MI9*^4"%X](,O[.3ZXN+Z-"/,&X2G8PG*-""C%N6"I?2*9MCK(HY0&)W;
MLH77O<07X4.V[$PJ_5&SM@* ,2$:'AABL+Q! \/",.Z?1=.)/')PGP.0KSY%
MG*-HPS2O+")>%94C**5CF><8%S\004#EC8<./$G#A^*!_,2R="?FQ- D*>P)
M\+9(VJQAD6]'AI7[<'-QI-@=!MP^N@R4&;WQ'?;:N\DG :TGU,@]\*OPG,C'
M4Q"EQD*Q]GEW$BVY-RF15N1^.%%97S;& _[#5K*X5Z-=3(Z2/6,+HD;!2K6B
M4UI"J*3/YX2S*1T5J6PD7%M*T70Y1J-F4*? .P TZ?!PH?>QH(&T\Q170"M-
M&&Q 9XADF1I(C(*8)GD\$M:7CY@M4>M=WJIRKR>4\^CEWH.MMCOU-AL#'$?A
MZ;'1^U,WQ9ND _ 1WQ(O50XB$F!!;9(:DM'_X;MFY\Q,6T+JNL'NB51R2M+_
M*S1C/'=]@!E5JL03IP^$2 HQ'6_GD?C+=YV_XC'O[T?+^!>6.>63GNS'WN\%
M&N4#Y\]=P$#>A$^13#Z"YAY&I/9=9 U:E8)R<G%[<5K4J@L*W$[J,R]1@\F9
M!N-++S:J9XG*-EG,5U($+VQRRG-\9<WR%<_QU;Q269(=.,Z!_/8BZ1V3P%C=
M65=1GC$IL+##^2VE;7@,O9-KC0HGIC^F?MP&-2<VJ-\(D"1JIZC=NZ+&AZA>
M%P$!()AK1OLD0.KL)IETQ.'.[^$^+3I"->;Z%N75I\H?#)\#SK89M9S>;L_O
M=D+FH%+8-53"B4BHUH(C"[B,'2OP0RR/X*)J['@ +UF9HH8UZ1&*\K%PS"-0
M<S MW@G@I 6U'5%1+QXW<P5$; $:!T5OXL4!)\82*P(;OG-KBM85#EBB9B&2
MO$A1)_4,R0?-'SXU[H$!- 8W,%EMG_1^-W<W^P17LP%_\*FJARR1E!+27-=C
MZC-<8#48+X3/BH_!RNEFP2?3Y(*:3#SQ)Y@6G-3\3I/WO9G;78%__3ABLFNS
M(DPL<\UDG0/JAJV2H1$+I*9@O0A?;0?E>S].]D.]C3P:.<DJ7K;%/$2H<+=J
M*E!X+]5N?6_H4\^HI%MW+MP==ED4._FZ&&EGZ)#9H.6Z/MWO<T5>:*=$+.4S
MSTC6I&GTPH;4!UV=I_Q(O9*MM!6NE0J77<OF%+??/S1[=+^X*1P7J9'KCL(>
MY55^9Y>S:S2R]$4P:Q3EGN?'M$P**2ML'3^Q_5#4!#I 59\N:F:OOB1RJ*%S
M'FC<2VAGMOL%/)R":(&91D:&1@I$ZFE9I@8(7U-E 30&8A!8?>R[PHI=7.[(
MZ<.MF)P/-__Z^)][0]7P7[QJ)Z5Q942##VR!)6^2^OP@#\=D+(.!QORK,X;;
M=0132BF*0Z=;DK/-:BFR^D9^T %Z2M!D':(.(,L0T(BJ#!%975#F.M(&("%
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M7?PX<R>^%S;%5EXX@14[45$12(=CZ#T.:VI,/S]_6\Y/:M1,8%XZCHH2L-6
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MP84IG])";"K#HAH-6'PBIW"4("6T)S#VI>@B>PPU*I 5N))U('&/,UU$EA5
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M\*V>O<+[H8^J]<)7<K(5:_,Z@^GB]15^]GU["K]&T=C]^?\#4$L! A0#%
M  @ "8%+6M3UW;5"$   @VH  !$              ( !     &5X96PM,C R
M-3 R,3$N:'1M4$L! A0#%     @ "8%+6I1OP2AC @  !@<  !$
M     ( !<1   &5X96PM,C R-3 R,3$N>'-D4$L! A0#%     @ "8%+6M7=
M$&6JIP  A]@  !0              ( ! Q,  &5X96PM,C R-3 R,3%?9S$N
M:G!G4$L! A0#%     @ "8%+6O^I3%PK"@  ?54  !4              ( !
MW[H  &5X96PM,C R-3 R,3%?;&%B+GAM;%!+ 0(4 Q0    (  F!2UK+7>1+
MK@8  .HP   5              "  3W%  !E>&5L+3(P,C4P,C$Q7W!R92YX
M;6Q02P$"% ,4    "  )@4M:Y&%613TZ  "(8P( '               @ $>
MS   97AE;#(P,C1Q-#(P,C1E>&AI8FET.3DQ+FAT;5!+!08     !@ & ) !
(  "5!@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exel-20250211_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20250211.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2025-02-11</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
